A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation
Top Cited Papers
Open Access
- 17 October 2002
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 16 (11) , 1877-1888
- https://doi.org/10.1046/j.1365-2036.2002.01372.x
Abstract
Background : Irritable bowel syndrome is a common functional gastrointestinal disorder which affects up to 20% of the population, with a predominance in females. Aim : To evaluate the efficacy and sa...Keywords
This publication has 26 references indexed in Scilit:
- The complexity of drug development for irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2002
- Tegaserod, a 5‐HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjectsAlimentary Pharmacology & Therapeutics, 2001
- Persistent placebo response during a year-long controlled trial of IBS treatmentGastroenterology, 2001
- Validation of a global relief measure in two clinical trials of irritable bowel syndrome with tegaserodGastroenterology, 2000
- Antinociceptive properties of HTF 919 (tegaserod), a 5-HT4 receptor partial agonist, on colorectal distension in ratsGastroenterology, 2000
- Irritable bowel syndrome: new pharmaceutical approaches to treatmentBest Practice & Research Clinical Gastroenterology, 1999
- Functional bowel disorders and functional abdominal painGut, 1999
- Review article: irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 1997
- Variability of gastrointestinal transit in healthy women and men.Gut, 1996
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988